Pulmonary imaging analytics company VIDA Diagnostics Inc Friday announced a notice of allowance for the patent "Systems and Methods for Quantifying Regional Fissure Features" that covers the collection, comparison and classification of patient fissures based on localised, image-derived characteristics.
The pending patent strengthens the company's existing intellectual property portfolio within fissure analytics and ELVR (Endobronchial Lung Volume Reductiontreatment) selection. Its VIDA|vision 2.1 features enhancements to the Lung Volume Analysis workflow for ELVR treatment selection and planning.
Additionally, the US patent 9,390,498, titled "Visualization and Characterization of Pulmonary Lobar Fissures," covers a framework for computing and displaying fissure integrity, a measure which serves as a surrogate for collateral ventilation, stated the company.
In conjunction, the company's US Patent 9,504,529 covers "Treatment Outcome Prediction for Lung Volume Reduction Procedures."
According to the company, its analysis goes beyond a global fissure assessment to provide highly precise regional fissure analyses and AI-powered predictions to locally characterize disease. Localized patient fissure features may be spatially mapped to and compared against those in a database of both responders and non-responders of a procedure, providing clinicians with valuable insights aimed to better inform clinical decisions.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review